ClinicalTrials.gg
CompletedNCT04261075Updated Aug 15, 2022

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

A Phase 1 interventional study of IPH5201 and durvalumab in Advanced Solid Tumors, sponsored by MedImmune LLC. Completed at 8 sites in 4 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2022-08-15.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 101 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Read the detailed description

Study D6770C00001 is a Phase 1, first-in-human, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, and immunogenicity of IPH5201 in adult subjects with advanced solid tumors, when administered as monotherapy or in combination with durvalumab ± oleclumab.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects; age ≥ 18 years
  • (ECOG) Performance Status of 0 or 1.
  • Subjects diagnosed with advanced solid tumors.
  • For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects must be to standard therapy or for which no standard therapy exists.
  • For Part 3 (IPH5201 combined with durvalumab and oleclumab): Subjects must have received and radiologically progressed on 1 for pancreatic ductal adenocarcinoma.
  • Subjects must have at least 1 according to v1.1.
  • Subjects must provide tumor specimens .

Exclusion criteria

Exclusion Criteria:

  • Receipt of any conventional or anticancer therapy (, anti-PD-1, anti-PD-L1 antibodies) within 21 days of the planned first dose.
  • Receipt of agents targeting CD73, CD39, or adenosine receptors.
  • Concurrent enrollment in another therapeutic clinical study.
  • Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent.

    • No toxicity leading to permanent discontinuation of prior IO therapy
    • Subjects must not have required the use of additional other than
  • Active or prior documented or inflammatory disorders within the past 5 years
  • Cardiac and vascular criteria:

    • Presence of myocardial infarction or unstable angina , or stroke, within 6 months.
    • Congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension
    • History of severe hypertension
    • History of any grade of blood clot within 6 months
  • Active infection, including tuberculosis; virus (HBV); virus (HCV); or (HIV)
  • Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study.
  • Other invasive within 2 years.
  • Major surgery within 28 days prior to first dose
  • Female subjects who are pregnant or breast feeding
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    IPH5201 monotherapy dose escalation

    IPH5201 monotherapy

    Biological: IPH5201

  • Experimental
    IPH5201 dose escalation with durvalumab

    IPH5201 plus durvalumab

    Biological: IPH5201 · Biological: durvalumab

  • Experimental
    IPH5201 dose escalation with durvalumab + oleclumab

    IPH5201 plus durvalumab and oleclumab

    Biological: IPH5201 · Biological: durvalumab · Biological: oleclumab

Interventions

  • BiologicalIPH5201

    Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

  • Biologicaldurvalumab

    Durvalumab Q3W for a maximum of 2 years

  • Biologicaloleclumab

    Oleclumab Q3W for a maximum of 2 years

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events as a measure of safety

    The primary endpoint is safety as assessed by the presence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs).

    Time frame: From time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months

  2. Incidence of clinically significant laboratory values as a measure of safety

    Number of subjects with clinically significant laboratory values from baseline including blood counts, liver, kidney and pancreas tests, electrolytes, and blood clotting.

    Time frame: From time of informed consent through 12 weeks after the last dose of investigational product, approximately 7 months

  3. Incidence of clinically significant electrocardiogram (ECG) abnormalities as a measure of safety

    12 lead ECGs will be measured to identify clinical significant abnormalities including ECGs that demonstrate a QTcF value \>500ms, 2 additional 12-lead ECGs should be obtained over a 30 minute time period to confirm prolongation based on the average QTcF value

    Time frame: From time of informed consent through treatment period and including the follow-up period 12 weeks after last dose of investigational product, approximatley 7 months

Secondary outcomes

  1. OR (Objective Response; Response evaluation criteria in solid tumors [RECIST] v1.1)

    Evaluate the primary antitumor activity of IPH5201 monotherapy or in combination with durvalumab +/- oleclumab (disease control)

    Time frame: From time of consent until date of first documented disease progression (approximately 4 months)

  2. DC (Disease Control; RECIST 1.1)

    Evaluate the primary antitumor activity of IPH5201 with durvalumab +/- oleclumab (disease control)

    Time frame: From time of consent until date of first documented disease progression (approximately 4 months)

  3. Half-life of IPH5201

    To characterize the pharmacokinetics of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab

    Time frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)

  4. Maximum serum concentration (Cmax) of IPH5201

    To characterize the pharmacokinetics of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab

    Time frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)

  5. Area under the curve (AUC) of IPH5201

    To characterize the pharmacokinetics of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab

    Time frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)

  6. Serum trough concentrations (durvalumab)

    To determine the pharmacokinetics of durvalumab when administered in combination with IPH5201+/- oleclumab

    Time frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)

  7. Serum trough concentrations (oleclumab)

    To determine the pharmacokinetics of oleclumab in combination with durvalumab and IPH5201

    Time frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)

  8. Incidence of antidrug antibodies (IPH5201)

    To determine the immunogenicity of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab

    Time frame: From start of treatment until 90 days after end of treatment (approximately 7 months)

  9. Incidence of antidrug antibodies (durvalumab)

    To determine the immunogenicity of durvalumab in combination with IPH5201 ± oleclumab

    Time frame: From start of treatment until 90 days after end of treatment (approximately 7 months)

  10. Incidence of antidrug antibodies (oleclumab)

    To determine the immunogenicity of oleclumab in combination with IPH5201 + durvalumab

    Time frame: From start of treatment until 90 days after end of treatment (approximately 7 months)

07

Study locations

8 sites
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Providence, Rhode Island 02906, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Bordeaux Cedex, 33076, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Lausanne, 1011, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Jun 2022, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Feb 7, 2020
StartActual
Mar 3, 2020
Primary completionActual
Jun 16, 2022
CompletionActual
Jun 16, 2022
Last update
Aug 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04261075
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Feb 7, 2020
Start date
Mar 3, 2020
Primary completion
Jun 16, 2022
Completion
Jun 16, 2022
Last update
Aug 15, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion